Whilst these findings possibly suggest that permissively higher PTH in CKD may benefit HRQoL, due to contrasting directions of affect, this more likely reflects the heterogeneity of presentation in those with secondary hyperparathyroidism at differing stages of CKD and the authors strongly advise caution in its interpretation. The gene discussed is PTH; the disease is secondary hyperparathyroidism.